BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

878 related articles for article (PubMed ID: 34365081)

  • 1. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
    Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
    [No Abstract]   [Full Text] [Related]  

  • 4. Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.
    Stahler A; Stintzing S; von Einem JC; Westphalen CB; Heinrich K; Krämer N; Michl M; Modest DP; von Weikersthal LF; Decker T; Kiani A; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Kaiser F; Kirchner T; Jung A; Heinemann V
    Eur J Cancer; 2020 Sep; 137():250-259. PubMed ID: 32810748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
    Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
    Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of microsatellite instability by next-generation sequencing, MSI PCR and MMR immunohistochemistry in 1942 solid cancers.
    Kang SY; Kim DG; Ahn S; Ha SY; Jang KT; Kim KM
    Pathol Res Pract; 2022 May; 233():153874. PubMed ID: 35405622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
    Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel NGS-based microsatellite instability (MSI) status classifier with 9 loci for colorectal cancer patients.
    Zheng K; Wan H; Zhang J; Shan G; Chai N; Li D; Fang N; Liu L; Zhang J; Du R; Wu Q; Li X; Zhang C
    J Transl Med; 2020 May; 18(1):215. PubMed ID: 32466784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
    Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M
    Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
    Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
    Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
    Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
    Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
    Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
    Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium.
    Fenizia F; Alborelli I; Costa JL; Vollbrecht C; Bellosillo B; Dinjens W; Endris V; Heydt C; Leonards K; Merkelback-Bruse S; Pfarr N; van Marion R; Allen C; Chaudhary R; Gottimukkala R; Hyland F; Wong-Ho E; Jermann P; Machado JC; Hummel M; Stenzinger A; Normanno N
    J Mol Diagn; 2021 Jul; 23(7):882-893. PubMed ID: 33964449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
    Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
    Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing.
    Jan YH; Tan KT; Chen SJ; Yip TTC; Lu CT; Lam AK
    Br J Cancer; 2022 Oct; 127(7):1304-1311. PubMed ID: 35842545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic landscape of microsatellite instability in Chinese tumors: A comparison of Chinese and TCGA cohorts.
    Li Z; Jia Y; Zhu H; Yuan H; Xing X; Xin Y; Ma T; Pang F; Zhang Y; Hu Y; Jia S; Ji J
    Int J Cancer; 2022 Oct; 151(8):1382-1393. PubMed ID: 35567574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
    Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
    Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer.
    Randon G; Intini R; Cremolini C; Elez E; Overman MJ; Lee J; Manca P; Bergamo F; Pagani F; Antista M; Angerilli V; Ros Montaña FJ; Lavacchi D; Boccaccino A; Fucà G; Brich S; Cattaneo L; Fassan M; Pietrantonio F; Lonardi S
    Eur J Cancer; 2022 Jan; 161():90-98. PubMed ID: 34933155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
    Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
    JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.